PT862622E - Metodo de rastreio para compostos que interagem com proteina cinase rac - Google Patents

Metodo de rastreio para compostos que interagem com proteina cinase rac

Info

Publication number
PT862622E
PT862622E PT96938081T PT96938081T PT862622E PT 862622 E PT862622 E PT 862622E PT 96938081 T PT96938081 T PT 96938081T PT 96938081 T PT96938081 T PT 96938081T PT 862622 E PT862622 E PT 862622E
Authority
PT
Portugal
Prior art keywords
rac
screening
compounds
protein kinase
protein
Prior art date
Application number
PT96938081T
Other languages
English (en)
Inventor
Brian Arthur Hemmings
Cohen Philip
Alessi Dario
Cross Darren
Andjelkovic Mirjana
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9523379.7A external-priority patent/GB9523379D0/en
Priority claimed from GBGB9525704.4A external-priority patent/GB9525704D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT862622E publication Critical patent/PT862622E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT96938081T 1995-11-16 1996-11-05 Metodo de rastreio para compostos que interagem com proteina cinase rac PT862622E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9523379.7A GB9523379D0 (en) 1995-11-16 1995-11-16 Compound and method
GBGB9525704.4A GB9525704D0 (en) 1995-12-15 1995-12-15 Ligand and screening method

Publications (1)

Publication Number Publication Date
PT862622E true PT862622E (pt) 2005-01-31

Family

ID=26308124

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96938081T PT862622E (pt) 1995-11-16 1996-11-05 Metodo de rastreio para compostos que interagem com proteina cinase rac

Country Status (9)

Country Link
EP (1) EP0862622B1 (pt)
JP (1) JP4173544B2 (pt)
AT (1) ATE274053T1 (pt)
AU (1) AU7564396A (pt)
DE (1) DE69633186T2 (pt)
DK (1) DK0862622T3 (pt)
ES (1) ES2227614T3 (pt)
PT (1) PT862622E (pt)
WO (1) WO1997018303A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525703D0 (en) * 1995-12-15 1996-02-14 Ciba Geigy Ag Screening method
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
CA2214841A1 (en) * 1997-10-31 1999-04-30 Lisa Mckerracher Rho antagonists and their use to block inhibition of neurite outgrowth
SE9801530D0 (sv) * 1998-04-30 1998-04-30 Pharmacia & Upjohn Ab Method for screening
US6555732B1 (en) 1998-09-14 2003-04-29 Pioneer Hi-Bred International, Inc. Rac-like genes and methods of use
CA2622786A1 (en) * 1998-10-16 2000-04-27 Naoto Oku Neovascular-specific peptides
US7169783B2 (en) 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3
WO2000050452A1 (en) * 1999-02-26 2000-08-31 University College London Mutants of rac protein
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
SI1144600T1 (sl) * 1999-03-19 2008-12-31 Aventis Pharma Inc AKT-3-nukleinske kisline, polipeptidi in njihove uporabe
WO2001092499A1 (en) * 2000-05-30 2001-12-06 Moelling Karin NUCLEIC ACID MOLECULES ENCODING A PROTEIN INTERACTING WITH Ser/Thr KINASE Akt
US6689807B1 (en) 2000-06-08 2004-02-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA reductase inhibitors for promoting angiogenesis
GB0014185D0 (en) 2000-06-09 2000-08-02 Novartis Res Found Compound and method
DE60336576D1 (de) 2002-10-30 2011-05-12 Merck Sharp & Dohme Hemmer der akt aktivität
GB0227562D0 (en) 2002-11-26 2002-12-31 Novartis Forschungsstiftung Phorphorylated NDR Kinase
WO2006036613A2 (en) * 2004-09-17 2006-04-06 Exelixis, Inc Mracs as modifiers of the rac pathway and methods of use
EP3062790B1 (en) * 2013-11-01 2023-03-08 Pitney Pharmaceuticals Pty Limited Pharmaceutical combinations for the treatment of cancer

Also Published As

Publication number Publication date
JP4173544B2 (ja) 2008-10-29
DK0862622T3 (da) 2004-12-20
EP0862622B1 (en) 2004-08-18
EP0862622A1 (en) 1998-09-09
AU7564396A (en) 1997-06-05
JP2000500746A (ja) 2000-01-25
DE69633186T2 (de) 2005-08-18
WO1997018303A1 (en) 1997-05-22
ATE274053T1 (de) 2004-09-15
ES2227614T3 (es) 2005-04-01
DE69633186D1 (de) 2004-09-23

Similar Documents

Publication Publication Date Title
PT862622E (pt) Metodo de rastreio para compostos que interagem com proteina cinase rac
Satish et al. Interferon-inducible protein 9 (CXCL11)-induced cell motility in keratinocytes requires calcium flux-dependent activation of μ-calpain
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
DE69635671D1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
NO982055D0 (no) 2-alkylpyrrolidiner
DE69939864D1 (de) Ppar-gamma modulatoren
NO20013115L (no) En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes
DE69841434D1 (de) VERWENDUNG VON FVIIa ODER FVIIAi ZUR BEHANDLUNG VON ENDOTHELIALER FEHLFUNKTION BZW ZUR INHIBIERUNG DER ANGIOGENESE
ATE333465T1 (de) Methoden und mittel zur hemmung der cdk4- aktivität
DE69228997D1 (de) Menschliche il-3-varianten
ATE293254T1 (de) Modulierung von mlk- (multiple lineage kinase) proteinen
ATE382366T1 (de) Modifizierte myelin proteinmoleküle
CA2069611A1 (en) Method to Detect Bone and Other Connective Tissue Disorders in Humans and Animals
AU4711597A (en) Diagnosis of spongiform encephalopathy
DE60034779D1 (de) Insulinartiger-wachstumsfaktorbindungsprotein-4-protease
BR9305035A (pt) Agentes de curtimento e sua aplicaçáo
WO2004109290A3 (en) Methods for identifying modulators of kinesin activity
ATE278014T1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
DE69734890D1 (de) Rdgb-proteine
WO2003012103A3 (fr) Acides nucleiques codant de nouvelles proteines a boite f, leurs utilisations en diagnostic et en therapie
AU6193699A (en) Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1
WO2003012102A3 (fr) Acides nucleiques codant des proteines a domaine hect
WO2004083818A3 (en) Methods of identifying drug targets and modulators of neurons and compositions comprising the same
DK0864092T3 (da) Kompleks-bundne inhibitorer af aktiverbare stofskifteenzymer som molekylære markører til diagnosticering og terapiovervågning
SE0202608D0 (sv) New sequences